Immunity-and-Matrix-Regulatory Cells Derived from Human Embryonic Stem Cells Safely and Effectively Treat Mouse Lung Injury and Fibrosis

Jun Wu; Dingyun Song; Zhongwen Li; Baojie Guo; Yani Xiao; Wenjing Liu; Lingmin Liang; Chunjing Feng; Tingting Gao; Zai Wang; Jianyan Wen; Shengnan Yang; Peipei Liu; Lei Wang; Yukai Wang; Liang Peng; Guihai Feng; Shiqiang Huang; Glyn Nigel Stacey; Wei Li; Yan Huo; Ronghua Jin; Qi Zhou; Liu Wang; Baoyang Hu; Huaping Dai; Jie Hao

vs. IMRCs 70% (P<0.01), UCMSCs 52.63%, PFD 65% (P＜0.05)). Moreover, IMRC treatment showed 524 the best improvement in lung morphology (Fig. S7A ) and the best reduction in BLM-induced edema, as 525 measured by the lung coefficient (lung wet weight/total body weight), compared to UCMSCs or PFD 526 treatments (Fig. S7B) . 527 528 Functionally, mice treated with IMRCs showed the best improvements in indices for lung capacity, 529 including pressure-volume (PV), inspiratory capacity (IC), static compliance (Crs) and forced vital 530 capacity (FVC) (Fig. S8A , B, C, D). IMRC treatment also showed the best reduction in functional indices 531 for lung fibrosis, including respiratory resistance (Rrs), elastic resistance (Ers), tissue damping (G) and 532 tissue elasticity (H) were observed (Fig. S8E, F, G, H) . Computed tomography (CT) scans also showed 533 that IMRC treatment led to the best improvement in lung morphology, compared to UCMSCs or PFD 534 treatment (Fig. S8I, J) . In fact, measurements of the lung volume indicated that mice treated with IMRCs 535 had the best improvement in lung volume compared to UCMSCs or PFD treatments. These results 536 indicated that the IMRC therapy is superior to primary UCMSCs and pirfenidone in treating lung injury 537 and fibrosis. 538